Intercept Prescription drugs, Inc. (NASDAQ:ICPT – Get Score)’s inventory value traded down 3.2% throughout mid-day buying and selling on Tuesday after B. Riley lowered their value goal on the inventory from $30.00 to $28.00. B. Riley at present has a purchase score on the inventory. Intercept Prescription drugs traded as little as $17.51 and final traded at $17.57. 1,630 shares had been traded throughout buying and selling, a decline of 100% from the typical session quantity of 1,181,447 shares. The inventory had beforehand closed at $18.16.
Different analysts additionally not too long ago issued stories in regards to the inventory. Cowen lowered their value goal on shares of Intercept Prescription drugs to $22.00 in a report on Tuesday, August ninth. StockNews.com downgraded shares of Intercept Prescription drugs from a “purchase” score to a “maintain” score in a analysis be aware on Thursday, August 4th. Raymond James lifted their goal value on Intercept Prescription drugs from $23.00 to $26.00 and gave the corporate an “outperform” score in a analysis report on Thursday, August 4th. SVB Leerink decreased their value goal on Intercept Prescription drugs from $27.00 to $21.00 and set a “market carry out” score for the corporate in a analysis report on Friday, July eighth. Lastly, Needham & Firm LLC lowered their value goal on Intercept Prescription drugs from $25.00 to $22.00 and set a “purchase” score on the inventory in a analysis report on Friday, July eighth. Seven funding analysts have rated the inventory with a maintain score and three have given a purchase score to the inventory. In accordance with knowledge from MarketBeat, the inventory has a consensus score of “Maintain” and a mean value goal of $22.10.
Institutional Buying and selling of Intercept Prescription drugs
A number of institutional traders and hedge funds have not too long ago purchased and bought shares of ICPT. Amalgamated Financial institution acquired a brand new place in shares of Intercept Prescription drugs through the 1st quarter value roughly $66,000. Zurcher Kantonalbank Zurich Cantonalbank raised its place in shares of Intercept Prescription drugs by 63.9% within the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,879 shares of the biopharmaceutical firm’s inventory valued at $79,000 after buying an extra 1,903 shares through the interval. Fox Run Administration L.L.C. purchased a brand new place in shares of Intercept Prescription drugs within the second quarter valued at about $155,000. Operating Level Capital Advisors LLC acquired a brand new stake in shares of Intercept Prescription drugs through the 1st quarter value about $163,000. Lastly, Clear Creek Monetary Administration LLC purchased a brand new stake in shares of Intercept Prescription drugs through the 2nd quarter value about $176,000. Institutional traders personal 83.44% of the corporate’s inventory.
Intercept Prescription drugs Buying and selling Up 0.4 %
The agency has a market cap of $543.22 million, a price-to-earnings ratio of -8.41 and a beta of 1.25. The inventory’s 50 day shifting common is $14.67 and its 200 day shifting common is $15.68.
Intercept Prescription drugs (NASDAQ:ICPT – Get Score) final issued its quarterly earnings knowledge on Wednesday, August third. The biopharmaceutical firm reported ($0.68) earnings per share (EPS) for the quarter, lacking analysts’ consensus estimates of ($0.53) by ($0.15). The agency had income of $100.40 million through the quarter, in comparison with the consensus estimate of $94.85 million. On common, equities analysis analysts predict that Intercept Prescription drugs, Inc. will submit -2.92 EPS for the present yr.
About Intercept Prescription drugs
(Get Score)
Intercept Prescription drugs, Inc, a biopharmaceutical firm, focuses on the event and commercialization of therapeutics to deal with progressive non-viral liver illnesses in america, Europe, and Canada. The corporate markets Ocaliva, a farnesoid X receptor agonist used for the remedy of major biliary cholangitis together with ursodeoxycholic acid in adults.
Additional Studying
Obtain Information & Scores for Intercept Prescription drugs Each day – Enter your e-mail handle under to obtain a concise every day abstract of the newest information and analysts’ scores for Intercept Prescription drugs and associated corporations with MarketBeat.com’s FREE every day e-mail publication.
